Peripheral T-cell lymphoma - Not otherwise specified

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Critical reviews in oncology/hematology (Impact Factor: 4.03). 09/2011; 79(3):321-9. DOI: 10.1016/j.critrevonc.2010.07.007
Source: PubMed


Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) does correspond to a heterogeneous group of nodal and extranodal mature T-cell lymphomas, with a low prevalence in Western countries. PTCL-NOS accounts for about 25% of all PTCL, which represent over 15% of all lymphomas. In the lymph node, PTCL-NOS shows paracortical or diffuse infiltrates with effacement of the normal architecture, with a broad cytological spectrum and a frequently observed inflammatory background. Some morphological variants include: lymphoepithelioid or Lennert's type, T-zone, and follicular. PTCL-NOS is characterized by an aberrant T-cell phenotype, with frequent loss of CD5 and CD7. A CD4+/CD8- phenotype predominates in nodal cases. CD4/CD8 +/+ or -/- is at times seen, as is CD8, CD56 and cytotoxic granule expression. Ki-67 rate is typically high. TCR β-chain is usually expressed; TCR genes are most often clonally rearranged. PTCL-NOS typically occurs in adults (median age 55-60 years), with a higher prevalence in males. It presents more often as disseminated disease, occasionally with eosinophilia, pruritis or hemophagocytic syndrome. Patients often have B symptoms, generalized lymphadenopathy, bone marrow infiltration, and extranodal involvement, with high or high-intermediate IPI score in 50-70% of cases. Prognosis is poor, with a 5-year OS of 20-30%. Some variables, like ST2(L), CXCR5, CXCR3, EBV infection, cytotoxic granule expression, high proliferative index, NF-κB expression, were proposed as prognostic indicators, but the IPI score, and its variant called PIT, remains the most effective prognostic factor. Patients with PTCL-NOS should be treated with anthracycline-containing chemotherapy, followed by radiotherapy in cases of stage I-II disease. This strategy is associated with an overall response rate higher than 60%, but the 5-year overall survival is only 20-30%. Upfront high-dose chemotherapy supported by autologous or allogeneic SCT is an investigational approach, with a 4-year overall survival of about 40%. Patients with chemosensitive relapse respond favorably to high-dose chemotherapy and ASCT, with long-term survival rates of 35-45%. Graft-versus-lymphoma effect following allogeneic SCT has been observed; and reduced intensity conditioning emerges as an attractive strategy for frail patients. Most patients with PTCL-NOS are enrolled in prospective trials to explore new approaches, and new agents, like gemcitabine, alemtuzumab and pralatrexate, are being investigated.

Download full-text


Available from: Andrés José María Ferreri, Sep 08, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: We discuss the clinical presentation, investigations carried out, and the management issues in an elderly patient with hemophagocytic lymphohistiocytosis (HLH). The HLH was associated with an underlying Epstein-Barr virus positive peripheral T-cell lymphoma, not otherwise specified, and the lymphomatous cells harbored translocation t(5;9)(q11.2:p24). The 9p24 region contains the JAK2 gene. The disease had a fulminant course.
    No preview · Article · Mar 2011 · Leukemia & lymphoma
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined whether nm23-H1 is a prognostic factor of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). We studied 102 consecutive, untreated PTCL-NOS patients from 1998 to 2008. The expression of nm23-H1 and TIA-1 was studied by immunohistochemistry. nm23-H1 was positive in 44.1% and TIA-1 in 78.4% of the PTCL-NOS patients. nm23-H1 expression was not correlated with age, performance status (PS), lactate dehydrogenase (LDH) level, or stage but was significantly correlated with the prognostic index for T-cell lymphoma. The serum nm23-H1 level was 43.44 ng/mL in the cytoplasmic nm23-H1 strongly positive, 24.32 ng/mL in the cytoplasmic nm23-H1 moderately positive, and 13.64 ng/mL in the cytoplasmic nm23-H1-negative patients. The nm23-H1-positive group had significantly shorter overall survival (OS). TIA-1 had no prognostic impact on 5-year OS rates. OS was significantly shorter in patients with the following clinicopathologic features: age 60 or more years, PS of 2 to 4, LDH level greater than normal, bone marrow involvement, or nm23-H1-positive lymphoma. Multivariate analysis confirmed nm23-H1 expression to be an independent prognostic factor. The nm23-H1 protein may be an important prognostic factor in PTCL-NOS. Because our results suggested that nm23-HI is produced by lymphoma cells, we expect to see the development of new treatments targeting nm23 overexpression.
    Preview · Article · May 2011 · Clinical Cancer Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Periphere kutane T-Zell-Lymphome, deren morphologische und molekulare Variabilität keine weiterführende Klassifikation erlauben, werden innerhalb der Gruppe der primär kutanen peripheren T-Zell-Lymphome – nicht spezifiziert – (PCTL-NOS) zusammengefasst. Die PCTL-NOS stellen eine seltene, heterogene Gruppe dar, die sich in den meisten Fällen durch rasch auftretende Knoten ohne die für die Mycosis fungoides typischen Plaques, eine ungünstige Prognose und ein schlechtes Therapieansprechen auszeichnen. Wir berichten über einen 62-jährigen Patienten mit asymptomatischen Papeln im Bereich der Ellen- und Kniebeuge. Anhand histopathologischer Kriterien konnte die Diagnose eines PCTL-NOS gestellt werden. Vor dem Hintergrund von Genexpressionsstudien erhofft man sich ein Therapieansprechen auf Tyrosinkinase- und Histon-Deacetylaseinhibitoren. Peripheral cutaneous T-cell lymphoma which cannot be further classified due to high morphological and molecular variability are included into the group of “primary cutaneous peripheral T-cell lymphoma – not otherwise specified” (PCTL-NOS). PCTL-NOS represent a rare, heterogeneous group characterized by rapidly progressive nodules in the absence of typical mycosis fungoides plaques. Furthermore, therapeutic options are limited and prognosis is rather poor. We report on a 62-year-old patient presenting with asymptomatic papules in the popliteal and antecubital fossae. Based on histopathological criteria, PCTL-NOS was diagnosed. Based on recent gene expression studies, a positive reaction to tyrosine kinase and histone deacetylase inhibitors is hoped for. SchlüsselwörterT-Zell-Lymphom–Primär kutanes T-Zell-Lymphom–PCTL-NOS–Tyrosinkinaseinhibitoren–Histon-Deacetylaseinhibitoren KeywordsT-cell lymphoma–Primary cutaneous peripheral T-cell lymphoma–PCTL-NOS–Tyrosine kinase inhibitors–Histone deacetylase inhibitors
    No preview · Article · May 2011 · Der Hautarzt
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.